Posts by Maria Thacker
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
Atlanta, GA, May 24, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of updates on the development of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the Vaccines Summit Boston 2023 and…
Read MoreAtlanta medical device company Artelon to move into new office after capital infusion
May 24, 2023, 07:24am EDTMarietta-based medical device company Artelon has secured $20 million in Series B funding to support the commercial growth of its proprietary bio-textile for surgical repair of ankles and other joints. Venture capital firm Vensana led the round of financing for Artelon’s soft-tissue reconstruction material. Artelon expects additional funding from existing investors. …
Read MoreBoston Scientific signs Atlanta’s largest lease of 2023 at former State Farm campus
May 23, 2023 | Atlanta Business Chronicle: The deal is the latest development in growing the presence of life sciences companies in and around Atlanta. Subscription Required: https://www.bizjournals.com/atlanta/news/2023/05/23/boston-scientific-deal-johns-creek.html
Read MoreTCSG selected for National Science Foundation grants
May 22, 2023 | The Technical College System of Georgia (TCSG) is proud to announce its selection as the workforce partner for three U.S. National Science Foundation (NSF) Regional Innovation Engine grants in Georgia. These grants represent significant milestones in advancing cutting-edge research and innovation in key sectors, and TCSG is honored to be at…
Read MoreMicron Biomedical Announces Positive Measles and Rubella Vaccination Results from First Clinical Trial of Microarray Injection-Free Vaccine Delivery in Children
ATLANTA, May 17, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport, and storage of drugs and vaccines, today announced positive Phase 1/2 data from the first-ever clinical trial of microarray technology in children including infants as young as 9 months old. The study, which…
Read More